Biosynex SA (FR:ALBIO) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Biosynex’s subsidiary, Chembio Diagnostics, has received a $1.5 million grant from the Bill & Melinda Gates Foundation to develop a rapid diagnostic test for congenital syphilis, a growing global health concern. The test aims to offer a quick, accurate, and affordable solution, particularly in low and middle-income regions, enhancing early diagnosis and treatment of syphilis in newborns and pregnant individuals.
For further insights into FR:ALBIO stock, check out TipRanks’ Stock Analysis page.